Melanotan II (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors throughout the body. Originally developed at the University of Arizona in the 1980s as a potential sunless tanning agent and photoprotective compound, MT-II also produces potent sexual arousal and libido effects through central melanocortin receptor activity — making it one of the most multifaceted research peptides in terms of biological activity.
Research context only. The peptides and compounds discussed on WolveStack are research chemicals not approved for human use by the FDA. Nothing on this page constitutes medical advice. Consult a qualified healthcare professional before use.
Melanotan II activates melanocortin receptors throughout the body. At MC1R in skin, it stimulates melanin production for tanning and photoprotection. At MC3R/MC4R in the hypothalamus, it produces sexual arousal and libido enhancement.
How Does Melanotan II Work?
Melanotan II activates multiple melanocortin receptor subtypes. MC1R stimulation in skin melanocytes drives melanin synthesis — producing a tan without UV exposure and increasing photoprotective melanin before sun exposure. This was the original research objective: a compound that could reduce UV-induced skin cancer risk by pre-activating the skin's natural defense mechanism.
MC3R and MC4R activation in the hypothalamus produces the sexual arousal effects. These are the same receptors targeted by PT-141 (bremelanotide), which is a derivative of MT-II. The central melanocortin signalling pathway is a key regulator of sexual motivation and behaviour in both sexes.
MT-II is broader-acting than PT-141 — it activates more receptor subtypes with less selectivity. This produces stronger and faster tanning effects alongside sexual arousal, but also more side effects than PT-141's more targeted MC3R/MC4R profile.
Research History and Context
Melanotan II was developed by Norman Levine and colleagues at the University of Arizona with NIH funding. The original goal was photoprotection — activating melanin synthesis before UV exposure to reduce sunburn and skin cancer risk. Clinical trials in the 1990s confirmed the tanning effect but also revealed the potent sexual side effects, which led to a separate research programme that eventually produced PT-141/bremelanotide.
The compound never received regulatory approval and development was discontinued by Competitive Technologies (the commercialisation partner). However, the research peptide market adopted it widely, and it remains one of the highest-selling research peptides despite its unapproved status.
Safety concerns that contributed to the lack of regulatory development include: unpredictable melanocytic effects (darkening of existing nevi/moles, potential melanoma risk concerns), significant nausea at effective doses, blood pressure effects, and the broad melanocortin receptor activation producing diverse off-target effects.
What Is the Recommended Melanotan II Dosage?
| Use Case | Dose | Frequency | Notes |
|---|---|---|---|
| Tanning loading phase | 0.25–0.5 mg/day | Daily with sun exposure | Start low, assess tolerance |
| Tanning maintenance | 0.25–0.5 mg | 2–3x weekly | Maintain developed tan |
| Sexual effects | 0.5–1 mg | As needed, 1–2 hrs prior | Lower than tanning dose needed |
| Initial test dose | 0.1–0.25 mg | Once | Always start here first |
What Are the Side Effects of Melanotan II?
Melanotan II has a more significant side effect profile than PT-141, owing to its broader receptor activity.
**Nausea and flushing** are the most common and most dose-limiting side effects. Nausea can be severe, particularly at higher doses. Taking MT-II before sleep, staying hydrated, and keeping doses low reduces nausea incidence. Many users develop tolerance to nausea over 1–2 weeks of use.
**Mole and freckle darkening** is consistent and expected — MC1R activation stimulates melanin production in all melanocytes, not just background skin. Existing nevi (moles) darken and new freckles may appear. The concern about melanoma risk (could MT-II cause malignant transformation of atypical nevi?) has not been resolved in controlled studies but is a genuine theoretical concern. Individuals with atypical mole syndrome or high melanoma risk should approach with particular caution.
**Blood pressure changes** including mild elevations and occasional spontaneous erections in men at initial doses. Generally transient.
**Yawning and stretching** at onset of action — unusual but characteristic effects from central melanocortin activation. Often an early indicator the dose is active.
**Automatic tanning without sun exposure** is possible but less complete than with UV light. MT-II with UV exposure produces much more pronounced tanning than MT-II alone.
Research-Grade Sourcing
WolveStack partners with Ascension Peptides for independently third-party tested research compounds with published COAs. The links below go directly to the relevant products.
For research purposes only. Affiliate disclosure: WolveStack earns a commission on qualifying purchases at no additional cost to you.
Frequently Asked Questions
Melanotan II activates melanocortin receptors throughout the body. At MC1R in skin, it stimulates melanin production for tanning and photoprotection. At MC3R/MC4R in the hypothalamus, it produces sexual arousal and libido enhancement. It also has appetite-suppressing and blood pressure-modulating effects from broader melanocortin activity.
No — PT-141 (bremelanotide) is a derivative of MT-II designed specifically for sexual function with reduced receptor breadth. PT-141 has weaker MC1R activity (less tanning) and more selective MC3R/MC4R activity (cleaner sexual effects with fewer side effects). MT-II produces stronger tanning alongside stronger sexual effects but with more side effects from its broader receptor profile.
The cancer concern with MT-II is theoretical rather than documented. MC1R activation stimulates melanin production in all melanocytes, which theoretically could darken atypical moles or stimulate pre-existing melanocytic dysplasia. No controlled studies have confirmed MT-II causes melanoma, but the theoretical risk has been raised in the literature. Individuals with atypical moles, melanoma history, or strong melanoma family history are advised to avoid MT-II.
The tan developed with MT-II fades over 4–8 weeks after discontinuation at a rate similar to a natural UV-induced tan. During maintenance protocols (2–3 doses per week), the tan is sustained. The tan is real melanin — the same pigment produced by UV exposure — not a dye or self-tanner.
MT-II has no regulatory approval anywhere and is sold as a research chemical. In the US it is unscheduled and legal to purchase for research purposes. Australia has stricter peptide regulations. It is not legal to sell for cosmetic tanning purposes under FDA regulations.
Self-tanners (DHA-based products) react with dead skin cells on the surface to produce a temporary colour change — no melanin involved. Melanotan II stimulates actual melanin production in living melanocytes — the same biological process as UV tanning. The result is a real melanin-based tan with varying protection against UV damage, rather than a surface coating.